Loading...
•
Sep 30, 2022
Reviva Q3 2022 Earnings Report
Reported third quarter results and recent business highlights.
Key Takeaways
Reviva Pharmaceuticals reported a net loss of $3.5 million for the third quarter of 2022. As of September 30, 2022, the Company’s cash totaled approximately $23.2 million.
Over 30% enrollment in ongoing global, pivotal Phase 3 RECOVER trial
Topline data for Phase 3 RECOVER trial evaluating brilaroxazine for schizophrenia still expected mid-2023
Cash totaled $23.2M Million as of September 30, 2022
Announced $8.5 million registered direct offering and concurrent private placement in September 2022
Reviva
Reviva
Forward Guidance
Reviva anticipates several milestones and events, including enrollment initiation at sites in India for the RECOVER Phase 3 study expected in Q4 2022 and topline data for the pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023.
Positive Outlook
- Enrollment initiation at sites in India for RECOVER Phase 3 study expected in Q4 2022
- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023
- May initiate Phase 2a studies in bipolar disorder, MDD, ADHD, PAH and IPF subject to the receipt of non-dilutive financing in 2023
- Pursuing strategic partnership opportunities for the development of our pipeline
- Evaluating grant and other non-dilutive financing opportunities for product candidates from Federal and State Healthcare Agencies and Foundations